These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17224913)

  • 21. Nicotine metabolism defect reduces smoking.
    Pianezza ML; Sellers EM; Tyndale RF
    Nature; 1998 Jun; 393(6687):750. PubMed ID: 9655391
    [No Abstract]   [Full Text] [Related]  

  • 22. Metabolism and disposition kinetics of nicotine.
    Hukkanen J; Jacob P; Benowitz NL
    Pharmacol Rev; 2005 Mar; 57(1):79-115. PubMed ID: 15734728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tobacco addiction and pharmacogenetics of nicotine metabolism.
    Swan GE; Lessov-Schlaggar CN
    J Neurogenet; 2009; 23(3):262-71. PubMed ID: 19152209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Researches on the polymorphism of cytochrome P450 2A6].
    Tong Z; ZhuGe J; Yu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Oct; 19(5):424-7. PubMed ID: 12362322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
    Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
    Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?
    Quaak M; van Schayck CP; Knaapen AM; van Schooten FJ
    Eur Respir J; 2009 Mar; 33(3):468-80. PubMed ID: 19251795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort.
    Gambier N; Batt AM; Marie B; Pfister M; Siest G; Visvikis-Siest S
    Pharmacogenomics J; 2005; 5(4):271-5. PubMed ID: 15940289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases.
    Quaak M; van Schayck CP; Knaapen AM; van Schooten FJ
    Mutat Res; 2009 Jul; 667(1-2):44-57. PubMed ID: 19028511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
    Higashi E; Nakajima M; Katoh M; Tokudome S; Yokoi T
    Drug Metab Dispos; 2007 Apr; 35(4):508-14. PubMed ID: 17237153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2A6 polymorphism, nicotine, and environmental nitrosamines.
    Idle JR
    Lancet; 1999 Jun; 353(9169):2073. PubMed ID: 10376647
    [No Abstract]   [Full Text] [Related]  

  • 31. [Role of cytochrome P450 2A6 polymorphism in nicotine metabolism and tobacco-dependent behaviour].
    Xia XY; Peng RX
    Yao Xue Xue Bao; 2004 Sep; 39(9):758-63. PubMed ID: 15606031
    [No Abstract]   [Full Text] [Related]  

  • 32. [The relationship between smoking behavior in young people and CYP2A6 gene polymorphisms, between them and personality traits assessed by NEO-FFI].
    Waga C; Iwahashi K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2006 Aug; 41(4):380-6. PubMed ID: 17037346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
    Oscarson M
    Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genetics of nicotine metabolism.
    Mwenifumbo JC; Tyndale RF
    Handb Exp Pharmacol; 2009; (192):235-59. PubMed ID: 19184652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetic determinants of smoking.
    Batra V; Patkar AA; Berrettini WH; Weinstein SP; Leone FT
    Chest; 2003 May; 123(5):1730-9. PubMed ID: 12740294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms.
    Minematsu N; Nakamura H; Furuuchi M; Nakajima T; Takahashi S; Tateno H; Ishizaka A
    Eur Respir J; 2006 Feb; 27(2):289-92. PubMed ID: 16452582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.
    Lerman C; Jepson C; Wileyto EP; Patterson F; Schnoll R; Mroziewicz M; Benowitz N; Tyndale RF
    Clin Pharmacol Ther; 2010 May; 87(5):553-7. PubMed ID: 20336063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
    Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
    Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetics and smoking behavior.
    Schnoll RA; Johnson TA; Lerman C
    Curr Psychiatry Rep; 2007 Oct; 9(5):349-57. PubMed ID: 17915073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population.
    Kumasaka N; Aoki M; Okada Y; Takahashi A; Ozaki K; Mushiroda T; Hirota T; Tamari M; Tanaka T; Nakamura Y; Kamatani N; Kubo M
    PLoS One; 2012; 7(9):e44507. PubMed ID: 23049750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.